Efficacy and Safety Study of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa (HS)
Public ClinicalTrials.gov record NCT03487276. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to determine whether IFX-1 is safe and effective in the treatment of moderate to severe hidradenitis suppurativa.
Study identification
- NCT ID
- NCT03487276
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 179 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 26, 2018 (Actual)
- Primary completion
- May 27, 2019 (Actual)
- Completion
- Jan 27, 2020 (Actual)
- Last update posted
- Apr 8, 2021
2018 – 2020
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| InflaRX Investigational Site | Birmingham | Alabama | 35233 | — |
| InflaRX Investigational Site | Fort Myers | Florida | 33912 | — |
| InflaRX Investigational Site | Miami | Florida | 33136 | — |
| InflaRX Investigational Site | Sandy Springs | Georgia | 30328 | — |
| InflaRX Investigational Site | Dearborn | Michigan | 48124 | — |
| InflaRX Investigational Site | Columbia | Missouri | 65212 | — |
| InflaRx Investigational Site | Saint Joseph | Missouri | 64506 | — |
| InflaRX Investigational Site | St Louis | Missouri | 63104 | — |
| InflaRX Investigational Site | St Louis | Missouri | 63110 | — |
| InflaRX Investigational Site | Chapel Hill | North Carolina | 27516 | — |
| InflaRX Investigational Site | Cincinnati | Ohio | 45219 | — |
| InflaRX Investigational Site | Hershey | Pennsylvania | 17033 | — |
| InflaRx Investigational Site | Goodlettsville | Tennessee | 37072 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 28 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03487276, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 8, 2021 · Synced Oct 24, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03487276 live on ClinicalTrials.gov.